Why it matters: The signing of AB 1021 by Governor Newsom allows California doctors to prescribe MDMA and psilocybin medications if they are rescheduled at the federal level. This move prepares doctors for potential federal changes regarding the use of psychedelics in mental health treatment.
What they are saying: The bill states that if a substance listed under Schedule 1 is excluded from Schedule 1 of the Controlled Substances Act at the federal level, doctors in California can prescribe it. This applies to substances like MDMA, psilocybin, cannabis, and peyote. However, the bill specifically excludes cannabis and cannabis products because they are already addressed in other legislation.
The big picture: The FDA is expected to consider rescheduling MDMA and psilocybin, possibly as early as next year. Recent clinical trials have shown the effectiveness of MDMA in reducing symptoms of PTSD. The signing of AB 1021 aligns California’s laws with potential federal changes.
What to watch: Other bills related to cannabis and psychedelics are still awaiting the governor’s approval. These bills include decriminalizing psychedelics, restricting packaging options for cannabis companies, legalizing cannabis cafes, making changes to the track and trace system, allowing elderly patients to consume cannabis in hospitals, and preventing employers from asking about past cannabis use in job applications.
My take: The signing of AB 1021 is a significant step towards expanding access to psychedelic medications in California. By preparing doctors for potential rescheduling at the federal level, patients may have more options for mental health treatment. It will be interesting to see if other bills related to cannabis and psychedelics are also signed into law and how they will further shape the industry in California.
